NovaBridge Secures FDA Alignment for Accelerated Approval Pathway of Givastomig in Gastric Cancer

summarizeSummary

NovaBridge Biosciences announced FDA alignment for an accelerated approval pathway for its lead gastric cancer candidate, givastomig, paving the way for a registrational Phase 3 trial in Q4 2026.

check_boxKey Events

• FDA Alignment for Accelerated Approval

  The FDA confirmed givastomig's potential eligibility for an accelerated approval pathway in first-line Her2-, CLDN 18.2+, PD-L1+ gastroesophageal cancer patients.

• Registrational Phase 3 Trial Planned

  NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response rate (ORR) as a primary endpoint for accelerated approval.

• Positive Phase 1b Data Underpins Decision

  This regulatory milestone builds on robust efficacy and favorable tolerability observed in the Phase 1b combination trial, which showed a 75% objective response rate and 16.9-month median progression-free survival.

auto_awesomeAnalysis

This 6-K reports a significant regulatory milestone for NovaBridge Biosciences, as the FDA has confirmed givastomig's potential eligibility for an accelerated approval pathway in first-line gastric cancer. This alignment, based on compelling Phase 1b data, de-risks the development process and could expedite market access for a potential first-in-class therapeutic. The company plans to initiate a registrational Phase 3 trial in Q4 2026, which is a critical step towards commercialization.